{"id":"course-b2-vin","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a multi-agent chemotherapy regimen developed by the Children's Cancer Group in China for pediatric malignancies. Vincristine is a vinca alkaloid that binds to tubulin and disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis. The 'Course B2' component likely refers to a standardized protocol sequence that may include additional chemotherapy agents, though the exact composition is not publicly detailed in standard references.","oneSentence":"Course B2 + Vin is a chemotherapy combination regimen that uses vincristine (Vin) alongside other agents to inhibit microtubule formation and induce apoptosis in cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:07:47.131Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pediatric malignancies (specific indication not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT04881838","phase":"PHASE3","title":"CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2021-03-01","conditions":"Pediatric Anaplastic Large Cell Lymphoma","enrollment":172}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Course B2 +Vin","genericName":"Course B2 +Vin","companyName":"Children's Cancer Group, China","companyId":"children-s-cancer-group-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Course B2 + Vin is a chemotherapy combination regimen that uses vincristine (Vin) alongside other agents to inhibit microtubule formation and induce apoptosis in cancer cells. Used for Pediatric malignancies (specific indication not publicly detailed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}